While biological and lifestyle determinants of reproductive health are well documented globally, comprehensive data integrating socio-demographic, lifestyle, and health correlates within a contemporary Polish context remain limited. This study aimed …
Endometriosis is a chronic inflammatory and sex steroid hormone-dependent gynaecologic disease, characterised by endometrial cell proliferation outside the uterine cavity, often accompanied by fibrosis, progesterone resistance, and high recurrence despite …
Endometriosis (EMs) is a common gynecological disorder in women of reproductive age, often presenting with pelvic pain and infertility. Its progression is closely linked to estrogen levels. While hormonal therapies …
The aim was to explore the lived experiences of women diagnosed with endometriosis and receiving care in Spain to understand its impact across multiple areas of their lives. This qualitative …
Endometriosis is an estrogen-dependent disorder characterized by chronic inflammation, immune dysregulation, and altered hormone metabolism. Although gut microbiota-derived metabolites have been implicated in shaping immune microenvironments and lesion development, the …
Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
Endometriosis (EMs) is a widespread gynecological disease, affecting approximately 6-10% of females of child-bearing age. Despite its significant influence on women's health, the specific pathophysiology remains unclear. The enrichment of …
In 1999, Dr Susan Treloar and colleagues conducted a landmark twin study in Australia and reported their estimate of 51% for the heritability of endometriosis. This important result led several …
To evaluate the effectiveness and tolerability of dienogest in patients with endometriosis in real-world clinical practice.